Pharma-Bio Industry Capital Construction Monitor: Projects Underway in North America Represent $30 Billion Investment
Pharma-Bio Industry Capital Construction Monitor: Projects Underway in North America Represent $30 Billion Investment
Attachment: pharmabionorthamerica
SUGAR LAND--May 18, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Virtually every region of North America has a portion of the $30 billion worth of capital projects already in construction for the Pharmaceutical-Biotech Industry. A recent survey of Industrial Info's database revealed 416 North American pharma-bio projects with a cumulative total investment value (TIV) of $30.29 billion that are under construction.
Within this article: Lists projects underway developed by companies such as Baxalta (NYSE:BXLT), Procter & Gamble Company (NYSE:PG) and Johnson & Johnson's (NYSE:JNJ) (New Brunswick, New Jersey.
Additional companies: Fluor Corporation (NYSE:FLR)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Takeda Completes $62 Billion Shire Acquisition, an Industrial Info Market B...
- No Placebo Effect Needed as Life Science Sector Wraps Up $5.6 Billion in Pr...
- Top 10 U.S. States Land $37.7 Billion in Active Pharmaceutical-Biotech Indu...
- New Build Report: Pharmaceutical-Biotech Sector Plans 205 New Facilities wi...
- Pharma-Biotech Third-Quarter 2015 Update: $6.4 Billion of Investments in Pr...